Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has recommended continuation of its ongoing Phase 3 clinical trial of buntanetap in …
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said a newly published systematic review strengthens the scientific case for using topical statins to treat porokeratosis, a rare and progressive genetic …
Topical Statins Show Promise for Rare Skin Disease in New Review Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ATI-2138, showing rapid, near-complete, and sustained hair regrowth in a severe mouse model …
Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a …
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said newly published clinical trial data support the safety and early effectiveness of its experimental gene therapy for Stargardt disease, a rare inherited …
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage pipeline aimed at some of the most underserved rare skin …
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it has dosed the first patient in its global Phase 3 clinical program evaluating YCANTH (VP-102) for the treatment of …
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion Read More WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) said positive interim data from its first-in-human study of ATI-052 are accelerating the experimental drug’s push toward later-stage trials, signaling what the …
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will begin enrolling patients in January 2026 in a large, long-term study designed to assess whether its experimental Parkinson’s disease …
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug Read More